Almost two years after becoming Cytiva and joining the Danaher family, we asked Cetas Healthcare to look at how well the market is getting to know us in the diagnostics space. See highlights.
Almost two years after becoming Cytiva and joining the Danaher family, we are still something of a new kid on the block. We asked Cetas Healthcare to look at how well the market is getting to know us in the diagnostics space. Here are some highlights from the research.
- Our proof is in our products. Customers who try our products, buy from us at a higher rate than broadly across the industry. In fact, 75% of users who try our products then purchase from us, compared to the industry average of 65%. To determine a proxy for industry averages, researchers included a representative range of six competitors in the survey.
- In addition to proven product performance, the critical attributes for molecular diagnostics customers are ease of usage, product specifications, customization, and availability of support. Critical attributes for immunodiagnostics customers include simplified assay development process, availability of trial data, operational efficiency, and minimized process deviation.
- We are coming into our own. No doubt about it, we’ve grown by leaps and bounds over the past two years, and the life sciences industry is noticing. Awareness of Cytiva as a manufacturer of components and/or raw materials for diagnostic assays more than doubled, from 22% to 49%. Cytiva is being recognized as a global leader providing high performance, efficient products.
So, what’s on tap for the coming year? Part of the value of a study of this type is that it not only highlights success, but also illuminates areas for improvement. Continuous improvement is a core Cytiva (and Danaher) value, so you can be sure that we will be working on those areas, as well as building on our strengths.
Which critical attributes are most important to you? Try a sample question from our research study.